September 9th 2025
Zilebesiran’s twice-yearly dosing and sustained BP reductions could offer a new therapeutic approach for adults with resistant hypertension and high CV risk who are uncontrolled on current SOC regimens.
Tirzepatide Real-World Benefit Found Greater for CV, Renal Outcomes vs GLP-1 RAs in Adults with T2D
August 12th 2024In a head-to-head real world study, tirzepatide compared with semaglutide resulted in 42%, 20%, and 46% reduced risks for all-cause mortality and major adverse CV and renal events, respectively.